BIND Therapeutics Priced, Nasdaq: BIND
Biotech developing targeting mechanisms to enhance existing therapeutics.
Industry: Health Care
First Day Return: -6.1%
BIND
Biotech developing targeting mechanisms to enhance existing therapeutics.
| IPO Data | |
|---|---|
| IPO Date | 09/19/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $71 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2006 |
| Employees at IPO | 50 |
| Website www.bindtherapeutics.com | |
IPO News for BIND Therapeutics
BIND Therapeutics (BIND) Performance
